- Braxia Scientific enters a new chapter as it commences trading under its new ticker “CSE: BRAX” and rebrands its growing network of leading clinics to Braxia Health, which includes the Canadian Rapid Treatment Centre of Excellence established in 2018.
- Only clinic in Canada previously involved in a randomized controlled pivotal trial for regulatory approval purposes of psilocybin for the treatment of adults with depression.
- Led by Dr. Roger McIntyre, the top-rated expert in depression since 2010 as rated by Expertscape, Braxia Health has the largest clinical research footprint for ketamine and psychedelic-based research in the world, providing the fastest route to development of its IP capable formulations and IP capable delivery methods.
- First community-based centre in Canada to specialize in rapid-acting treatments for patients with treatment resistant major depressive disorder and bipolar disorder.
- First Ontario based centre licenced by the College of Physicians and Surgeons Ontario under the Out of Hospital Premises Program to perform ketamine IV treatments for depression.
- Over 3,000 intravenous Ketamine Infusions and 345 intranasal and sublingual Ketamine treatments administered to date in Canada.
- Focused on robust expansion throughout Canada, the U.S. and Europe by way of strategic acquisitions and organic growth of services to existing patients.
TORONTO, ONTARIO May 5, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (FWB: 496) (OTCQB: SHRMF), is pleased to announce the rebranding of its growing network of research and treatment clinics to Braxia Health. The Company also provided an update on its plan to expand its research and treatment and clinic footprint to address significant opportunities in the North American multi-billion-dollar mental healthcare market. Additionally, Braxia Scientific commenced trading under its new ticker “CSE: BRAX”.
“Since the founding of the initial Braxia Health clinic in 2018, we have built an innovative and disruptive healthcare business with the largest research footprint in the world for the emerging psychedelics industry,” said Dr. Roger S. McIntyre, Chief Executive Officer, Braxia Scientific and President of Braxia Health. “In addition to providing clinical care with novel treatments to patients suffering from depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other rapid-acting treatments. We are focused on becoming a vertically integrated global group of mental healthcare clinics setting the standard of care through peer reviewed industry protocols, in a market that is underserved and presents significant opportunity for growth.”
Braxia Health, the first of its kind in Canada, is a network of multidisciplinary outpatient clinical research treatment facilities specialized in providing breakthrough rapid-acting treatments for depression, such as intravenous ketamine and intranasal esketamine, which help patients suffering from several treatment-resistant conditions such as major depressive disorder or bipolar disorder. To date, the Company has launched 4 clinics in Canada and is seeking to add additional clinics in 2021 in North America and Europe.
Ketamine and Esketamine Delivering Results
Ketamine and Esketamine are the first rapid-acting antidepressants that have demonstrated the ability to significantly improve depressive symptoms within 24 hours. Both treatments represent the first treatments for depression that are mechanistically different from the antidepressants that have been available for the past 70 years. In addition to being highly effective, they have demonstrated to offer rapid symptom relief, especially in persons who have not benefited from conventional antidepressant approaches. In addition, evidence now indicates that both ketamine and esketamine are effective in persons affected by depression and suicidality.
About Braxia Scientific Corp.
Braxia Scientific is a research driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (Braxia Health) and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre“
Dr. Roger S. McIntyre
Chairman & CEO
– 30 –
FOR FURTHER INFORMATION PLEASE CONTACT: Braxia Scientific Corp. (416) 762-2138
Media: firstname.lastname@example.org, 416 822-2288
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”
Forward-looking statements include statements about the intended promise of ketamine and esketamine-based treatments for depression, and the potential for ketamine to treat other emerging psychiatric disorders, for the Company to be a leader in this space and for the Company’s ability to grow its clinical network.
Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.
Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward looking-statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.